Drug Shortage Report for HYOSCINE BUTYLBROMIDE INJECTION BP

Last updated on 2025-10-24 History
Report ID 255280
Drug Identification Number 02508419
Brand name HYOSCINE BUTYLBROMIDE INJECTION BP
Common or Proper name HYOSCINE BUTYLBROMIDE
Company Name OMEGA LABORATORIES LIMITED
Market Status MARKETED
Active Ingredient(s) HYOSCINE BUTYLBROMIDE
Strength(s) 20MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 10 x 1 mL vial / fiole
ATC code A03BB
ATC description BELLADONNAAND DERIVATIVES, PLAIN
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2025-06-30
Actual start date 2025-06-30
Estimated end date 2025-10-31
Actual end date 2025-10-23
Shortage status Resolved
Updated date 2025-10-24
Company comments Sandoz is covering Juno's hospital contracts.
Health Canada comments
Tier 3 Status No
Contact Address 11177 HAMON
MONTREAL, QUEBEC
CANADA H3M 3E4
Company contact information info@omegalaboratory.com - 1-800-363-0584

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v27 2025-10-24 English Compare
v26 2025-10-23 French Compare
v25 2025-10-23 English Compare
v24 2025-10-01 French Compare
v23 2025-10-01 English Compare
v22 2025-10-01 French Compare
v21 2025-10-01 English Compare
v20 2025-09-18 French Compare
v19 2025-09-18 English Compare
v18 2025-09-03 French Compare
v17 2025-09-03 English Compare
v16 2025-09-03 English Compare
v15 2025-08-18 French Compare
v14 2025-08-18 English Compare
v13 2025-08-11 French Compare
v12 2025-08-11 English Compare
v11 2025-07-01 French Compare
v10 2025-07-01 English Compare
v9 2025-07-01 English Compare
v8 2025-05-16 French Compare

Showing 1 to 20 of 27